Skip to content

PROGRESS-Lipedema study for clinical and biological phenotyping of affected patients

PROGRESS-Lipedema study for clinical and biological phenotyping of affected patients - PROGRESS-Lipedema

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00031231
Enrollment
100
Registered
2025-10-09
Start date
2023-01-05
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lipedema E88.2

Interventions

Group 1: Clinical and anthropometric measurements as well as metabolic and laboratory analyses and imaging in patients with stages 1–4 lipedema. Group 2: Control group: Clinical and anthropometric mea

Sponsors

UKR
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
16 Years to 99 Years

Inclusion criteria

Inclusion criteria: Lipedema St. 1-4 Control group: Women without a lipedema diagnosis, matched for age and BMI, without relevant chronic diseases.

Exclusion criteria

Exclusion criteria: Pregnancy

Design outcomes

Primary

MeasureTime frame
Occurrence of edema in the legs, pressure pain, skin appearance, body fat percentage, weight, waist-hip ratio (WHR), circumference measurements, and comprehensive metabolic and lipoprotein analysis using NMR spectroscopy. Time of assessment: once at the start of the study (baseline). Measurement methods: clinical examination, anthropometric measurements, bioimpedance analysis, and NMR spectroscopy.

Secondary

MeasureTime frame
Depression tendency (PHQ-9) – Assessment at the start of the study using a standardized questionnaire (PHQ-9). LEFS (Lower Extremity Functional Scale) – Assessment at the start of the study using a validated questionnaire. Eating habits – Assessment at the start of the study using a standardized dietary questionnaire (e.g., FFQ). General health status – Survey at the start of the study using self-report (VAS) and medical assessment. Evaluation of fibrosis and fat content – Once at the start of the study using elastography and Controlled Attenuation Parameter (CAP). Evaluation of lipedema vascularization – once at the start of the study using color-coded duplex sonography, B-flow, and microvascular imaging (MVI). Dual-energy X-ray absorptiometry (DXA) – once at the start of the study to determine body composition.

Countries

Germany

Contacts

Public ContactSally Kempa

UKR

sally.kempa@ukr.de+49 941 9440

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026